Amgen Inc. vs Apple Inc.: Strategic Comparison

This in-depth comparison examines Amgen Inc. and Apple Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating Apple Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and Apple Inc. is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $416.2B for Apple Inc., while their respective market capitalizations stand at $153.0B and $3.50T. Amgen Inc. is headquartered in United States and Apple Inc. operates from United States, and those different home markets shape how each company competes.

Amgen Inc.: A Japanese brewery kept Amgen alive. The upfront payment kept Amgen's laboratory lights on. Five years later, EPO became the first blockbuster drug in biotechnology history. The Kirin deal was not charity; it was a calculated exchange of geographic rights for survival capital. Without it, there might be no Amgen. The FTC sued to block the deal, arguing that Amgen could use its portfolio rebate structures to foreclose competing drugs from formularies. The companies won in court and closed the transaction. The companies won. The acquisition closed. It was the most expensive biotech deal of the year and among the largest in a decade, financed primarily with debt that raised Amgen's leverage ratio significantly. Thousand Oaks, California, 1980. In 1983, scientist Fu-Kuen Lin cloned the gene for erythropoietin, the hormone that signals bone marrow to produce red blood cells. Chemotherapy destroys bone marrow's ability to produce those cells, leaving cancer patients severely anemic and requiring frequent blood transfusions. A synthetic EPO could eliminate the need for transfusions. The FDA approved Epogen in 1989.

Apple Inc.: They're wrong. That's more annual revenue than Netflix, Spotify, and Adobe combined. The iPhone isn't the product. He runs a toll booth with 2.2 billion active devices passing through it every day. And yet the interesting question isn't how big Apple is. It's how long the model holds when regulators in Brussels and Washington are actively trying to pry open the walled garden that makes all of this work. That sounds cynical, but the numbers bear it out. But here's what the revenue split obscures: the iPhone isn't really a standalone product anymore. The average Apple household owns 3-4 devices. Services: The Real Margin Engine The App Store, where Apple takes 15-30% of every transaction from 1.8 million apps. Apple Music, Apple TV+, Apple Arcade, Apple News+, Fitness+, and the Apple One bundle that packages them together. AppleCare extended warranties. Services gross margins exceed 70%. Hardware margins sit around 36%. Every dollar that shifts from hardware to services makes Apple more profitable without selling a single additional device. That's the compounding engine Wall Street loves. The Supporting Cast They're network glue. The Capital Return Machine This isn't just shareholder friendliness — it's a structural choice. It's in the accumulated weight of 2.2 billion devices, each one generating recurring revenue and raising the cost of departure. You'd need to replicate the hardware, the OS, the chip design, the app network, the retail stores, the privacy brand, and the migration path — simultaneously. Nobody's doing that. But the iPhone's strategic function has shifted. The average iPhone user upgrades every three to four years. The Services relationship, once established, rarely ends. The Act's App Store provisions require Apple to allow alternative payment systems and third-party app stores on iPhones sold in Europe, directly attacking the mechanism by which Apple collects 15-30% of every digital transaction on its platform. It's Huawei. And the reason tells you everything about where Apple is actually vulnerable. In late 2023, the Mate 60 Pro appeared with a 7nm chip nobody in the West expected. By 2025, Huawei reclaimed double-digit smartphone share in China while Apple's share dropped below 15% in the country. It just needs to make Apple irrelevant in the world's largest smartphone market, and it's doing exactly that. They ship more phones, move faster on hardware form factors, and compete across every price tier from $150 to $1,800. The Galaxy S series matches iPhone spec-for-spec most years. Apple wins on captivity. If Gemini can manage your life, write your emails, organize your photos, and anticipate your needs better than anything Apple offers, then iOS stops being the reason you buy an iPhone. You buy whatever runs the best AI. They own the workplace. Apple has never cracked enterprise in a meaningful way. The Mac is tolerated in corporate environments, not preferred. Each attack hits a different wall of the fortress. And Apple's fortress has many walls. Apple doesn't need to win every battle. It needs to avoid losing all of them at the same time. That dip — the only year of revenue decline in over a decade — reflected consumer spending pressure and a challenging PC market. It had no lasting effect. Hardware gross margins run approximately 35-40% on iPhone, lower on Mac and iPad. Services margin differential means every dollar of Services revenue is worth nearly twice the profit of a dollar of hardware revenue. The iPhone revenue concentration — over 50% of total revenue from a single product category — creates structural exposure to any factor that disrupts the two-year replacement cycle: economic recession, geopolitical disruption to Taiwan Semiconductor supply chains, or competitive pressure from Android manufacturers gaining traction in the premium segment. The EU Digital Markets Act already forces Apple to allow sideloading and alternative payment systems in Europe. Epic Games won the right to external payment links. Apple depends on Chinese manufacturing (Foxconn, Pegatron, Luxshare) for the majority of iPhone assembly while simultaneously selling into China for roughly 17% of revenue. If US-China tensions escalate further, Apple faces the nightmare scenario of supply disruption and demand collapse happening at the same time. Then there's the AI gap. Apple shipped. A promise called Apple Intelligence that requires the newest hardware and still can't do half of what ChatGPT does. If consumers decide AI capability matters more than AI privacy, Apple's differentiation becomes a limitation. I'll make it concrete. My family has four iPhones, two MacBooks, an iPad, two Apple Watches, and AirPods for everyone. We have 11 years of photos in iCloud. Our group chats are in iMessage (and yes, the blue bubble thing is real social pressure among teenagers). My wife's health data — menstrual tracking, heart rate history, sleep patterns — lives in HealthKit with no export path to Android. We have $400+ in purchased apps. Family Sharing manages screen time for our kids. Find My tracks our AirTags on luggage and keys. Apple Pay is configured on every device. Switching to Android would take weeks of active migration work, and we'd still lose data. That's a hostage situation dressed up as convenience. And Apple has 2.2 billion devices worth of hostages. Apple's A-series and M-series chips deliver performance-per-watt that Qualcomm and Intel can't match because Apple controls both the hardware and the software stack. The M-series Mac transition wasn't just a spec bump — it gave MacBooks 15-20 hour battery life and silent operation that fundamentally changed what a laptop could be. Privacy has become the cherry on top. Cynical? Maybe. Effective? Absolutely. For consumers who care about data protection, Apple is the only credible choice among the major platforms. Services is the primary lever. Apple Intelligence is the hardware upgrade catalyst. By restricting AI features to iPhone 15 Pro and newer, Apple created artificial obsolescence for 1.5+ billion older devices. If the AI features prove genuinely useful — better Siri, smart summaries, image generation — they could compress the upgrade cycle from 4 years back toward 3. Health is the long game. Apple Watch already does ECG, blood oxygen, crash detection, and fall detection. Non-invasive glucose monitoring — if they crack it — would be the most significant health technology breakthrough in decades and would make Apple Watch medically indispensable for hundreds of millions of diabetics and pre-diabetics worldwide. That's not a product upgrade. That's a category transformation. Tata and Foxconn facilities in India are already assembling iPhones for export. Vision Pro? I'm skeptical in the near term. At $3,499, it's a developer kit priced as a consumer product. The real bet is that spatial computing becomes a platform in 5-7 years, and Apple wants to own the network before it matters. Everything depends on one variable: whether Apple Intelligence becomes genuinely useful before the market decides it's permanently behind in AI. The upgrade cycle compresses as 1.5 billion older iPhones become functionally obsolete. If Apple Intelligence remains a marketing label stapled onto mediocre features — if Siri still can't set two timers reliably while ChatGPT is writing code — then the narrative shifts permanently. Consumers start choosing phones based on AI capability rather than network. The blue bubble loses its grip when the green bubble has a better assistant. The regulatory question matters, but it's secondary. Steve Wozniak had built a computer circuit board that he wanted to share with friends at the Homebrew Computer Club. Steve Jobs saw something different: a product that ordinary people, not just engineers, might want to buy. The Apple I sold 200 units. Apple had found its first killer application. The 1984 Macintosh introduced the graphical user interface to the mass market, drawing on technology developed at Xerox PARC that Jobs had seen and recognized as defining before Xerox understood what it had. The Mac was expensive, partially closed, and initially sold in limited volumes. These aren't independent businesses. Tim Cook became CEO in 2011, inheriting the company Steve Jobs had rebuilt from near-insolvency in the late 1990s. App Store revenue is the highest-margin component of the highest-margin segment in the company. Huawei doesn't need to beat Apple globally. That's tens of billions in incremental iPhone revenue without acquiring a single new customer. Apple cannot survive being perceived as the company that missed the most important technology transition since mobile. Wozniak and Jobs retained the company. VisiCalc, the first spreadsheet software, ran on the Apple II and created the business case for personal computers in commercial settings. Jobs was forced out of the company by the board in 1985.

Amgen Inc. and Apple Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and Apple Inc..

Amgen Inc. business model: This segment has lower margins than branded biologics but provides volume growth and demonstrates Amgen's commitment to lower-cost medicine access — a narrative that carries important political value during a period of intense congressional scrutiny of drug pricing. The problem is, Amgen's operating margins have typically run between 30% and 35% on a GAAP basis and higher on an adjusted basis, reflecting both the pricing power of its branded biologics and decades of operational refinement. Amgen's financial profile in fiscal year 2024 reflected both the far-reaching impact of the Horizon Therapeutics acquisition and the ongoing pressure from patent expirations and pricing pattern. Ten drugs were subject to the first round of negotiations for 2026 pricing, and Enbrel was among the drugs selected for the second cycle of negotiations targeting 2027. It added Tepezza for thyroid eye disease and Krystexxa for chronic refractory gout — rare disease assets with high per-patient pricing and limited competition.

Apple Inc. business model: It's a subscription business disguised as a consumer electronics brand — one that happens to sell the most profitable physical objects ever manufactured. And it runs at 70%+ gross margins, nearly double what the hardware earns. It's the customer acquisition cost for a lifetime of App Store commissions, iCloud storage fees, AppleCare renewals, and a $20 billion annual check from Google just to remain the default search engine. The company designs and sells iPhone, Mac, iPad, Apple Watch, AirPods, and a growing services portfolio. It's a distribution mechanism for everything else Apple sells. Yet each one deepens the data gravity that makes switching to Android feel like moving countries. ICloud subscriptions from hundreds of millions of users who didn't realize 5GB of free storage would fill up in three months. Apple Pay transaction fees. It's the entry point into a services relationship that generates App Store commissions, iCloud subscriptions, Apple Music fees, Apple TV+ subscriptions, and Apple Pay transaction revenue across a lifetime that typically spans decades. In premium markets, captivity pays better. It needs to make Apple's software feel outdated. It's the European Commission. Each ruling chips away at the 15-30% commission structure that makes Services so obscenely profitable. What Apple has is something more like gravity — the accumulated pull of years of personal investment that makes leaving feel physically painful. It makes a $1,599 MacBook Pro feel safe because Genius Bar exists. Physical retail builds trust for premium pricing in a way that Amazon product pages never will. The Google Search deal ($20B+/year), App Store commissions, iCloud upsells, and the Apple One bundle all compound as the installed base grows. Apple can survive paying smaller App Store commissions.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of Apple Inc..

Amgen Inc. competitive advantage: Before the first human clinical trial ever tested a biotech-derived protein drug, a small group of venture-backed scientists in a repurposed building in Newbury Park, California, were betting that living cells could be engineered to manufacture medicines at industrial scale — a concept so novel in 1980 that most of Wall Street barely had a vocabulary for it. What makes Amgen genuinely unusual among its peers is the combination of scientific credibility, manufacturing scale, and financial discipline it has maintained over four decades. That singular achievement — turning living cells into life-saving medicines at global scale — is the defining fact of Amgen's half-century existence. Amgen's business model is built on one of the most capital-intensive and intellectually demanding processes in American enterprise: translating fundamental biological discoveries into regulated, manufactured medicines that can be sold at scale. Amgen's manufacturing organization is among the most sophisticated in the biopharma industry, running validated large-scale biologic production at facilities in Thousand Oaks, California; West Greenwich, Rhode Island; Juncos, Puerto Rico; Breda, Netherlands; and Singapore. While Amgen's MariTide program represents a genuine opportunity, it enters a market where Eli Lilly's Zepbound (tirzepatide) and Novo Nordisk's Wegovy (semaglutide) have already established billion-dollar revenue bases and massive manufacturing advantages. Amgen's most durable competitive advantage is its manufacturing expertise in large-molecule biologics. Financially, Amgen's scale generates operating use that smaller biotech firms cannot match. EPO had been identified and partially characterized in previous research, but no one had successfully cloned the human EPO gene and produced recombinant EPO protein at meaningful scale. The recombinant DNA tools available in 1980 were primitive by modern standards, but they were sufficient to do something that had never been done: clone human genes, insert them into bacterial or mammalian cell cultures, and produce therapeutic proteins at commercial scale.

Apple Inc. competitive advantage: The M-series chips gave MacBooks a genuine performance and battery advantage that Intel never could. Notice something odd about this model: it's almost impossible to compete with because the advantage isn't in any single product. Drop the word "moat" for a moment. That's not a moat. The silicon advantage is the technical layer underneath. The privacy angle transforms from limitation to advantage.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and Apple Inc. each plan to expand from here.

Amgen Inc. growth strategy: But those same drugs carry price tags that have triggered congressional hearings, federal investigations, and public outrage. Amgen generates revenue through four primary mechanisms: branded biologic product sales in the United States, international product sales in Europe and other markets, licensing and royalty income from partnerships, and a rapidly expanding biosimilars portfolio. Key pipeline assets include MariTide (maridebart cafraglutide), an investigational obesity and diabetes drug that targets both GLP-1 receptor agonism and GIP receptor antagonism — a mechanism that could position Amgen to compete directly with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide in the exploding weight loss drug market. The company has also advanced AMG 133 through Phase 2 trials with weight loss data that attracted significant investor attention in 2024 and 2025. The capital investment required to build and validate these facilities — routinely running into hundreds of millions or billions of dollars per site — creates a structural barrier that reinforces Amgen's competitive position. The company has invested in next-generation multiproduct manufacturing facilities that can be adapted to different biologic drug types with shorter reconfiguration times, improving capital efficiency. Capital allocation historically favored a combination of R&D reinvestment, dividend payments (the quarterly dividend reached $2.25 per share in 2024, yielding approximately 3%), and share repurchases. While the United States accounted for approximately 75% of product revenues in 2024, the company has been growing its ex-U.S. Presence, particularly in Europe where biosimilars face more receptive regulatory and market environments than in the U.S. Amgen's European commercial infrastructure, bolstered by its 2013 acquisition of deCODE Genetics in Iceland and longstanding partnerships across major EU markets, provides both revenue diversification and access to genomic research populations that inform drug discovery. Amgen Inc. was established at the dawn of the biotechnology era and has grown to become the archetype of what a successful independent biotech company can achieve. The company is organized into research and development divisions focused on oncology, cardiovascular and metabolic diseases, inflammation, bone health, rare diseases, and neuroscience. Amgen's competitive posture has evolved from a largely defensive stance in the early 2010s — when it was focused primarily on defending Enbrel and Neulasta from biosimilar competition — toward a more aggressive offensive strategy combining pipeline development, strategic acquisitions, and biosimilar market entry. The question of how much revenue Amgen can sustain through the mid-2020s patent cliff cycle while simultaneously growing new franchises defines the company's near-term financial trajectory. Amgen's growth strategy rests on four interdependent pillars that CEO Robert Bradway has consistently articulated to investors since 2020. Tepezza has significant underpenetrated market opportunity — the vast majority of thyroid eye disease patients remain undertreated despite Tepezza's strong clinical evidence — and Amgen has invested heavily in patient identification programs, specialist education, and payer coverage expansion since the acquisition closed. The third pillar is building the biosimilars business into a durable revenue contributor. Amgen has committed to launching biosimilar versions of multiple high-revenue biologics as they lose exclusivity through 2030, using its manufacturing capabilities to achieve cost structures that enable profitable competition at biosimilar price points. The fourth pillar is disciplined financial management — specifically debt reduction from the Horizon acquisition while preserving R&D investment and the dividend. Management has targeted returning to investment-grade credit metrics by 2027, which would restore full capital allocation flexibility including potential smaller bolt-on acquisitions in therapeutic categories where Amgen wants to build pipeline depth. The geographic growth opportunity in emerging markets, particularly China and Japan, where Amgen is building direct commercial presence, represents a longer-term revenue diversification vector. Amgen is attempting to offset this through volume growth in Repatha, Otezla, Tepezza, and biosimilars, while simultaneously advancing pipeline assets in oncology including tarlatamab (AMG 757), a bispecific T-cell engager targeting DLL3 for small cell lung cancer that received FDA accelerated approval in May 2024. Tarlatamab's launch performance will be an important indicator of Amgen's ability to build new oncology franchises beyond its historical reliance on supportive care drugs. Bowes, a partner at the venture firm U.S. Venture Partners, conceived the idea of building a biotech company from the ground up with experienced professional management at its helm rather than waiting for academics to evolve into businesspeople. Rathmann was not a molecular biologist, but he was a scientist with deep industry experience and an intuitive understanding of how to build research organizations. The company's initial scientific strategy was deliberately broad: it would pursue multiple research directions in protein biology simultaneously, betting that some would eventually yield commercial products without pre-committing to any single therapeutic hypothesis. Amgen moved its operations to a leased building in Newbury Park, California (later incorporated into Thousand Oaks), hiring scientists from Caltech, UCLA, and major pharmaceutical companies. This partnership, unconventional in the extreme — a biotechnology company licensing its core technology to a brewery — demonstrated the creative financial pragmatism that would characterize Amgen's management style for decades. The dual-product base gave the company the financial stability to invest in a research pipeline that would take two more decades to produce its next generation of commercially significant medicines.

Apple Inc. growth strategy: Apple doesn't need the cash for operations, and reducing share count mechanically increases earnings per share even when revenue growth slows. The company's blended margins improve as Services grows faster than hardware. The buyback program has been one of the most effective capital return mechanisms in corporate history, compounding per-share earnings growth beyond what operating income growth alone would produce. You can't diversify away from China in three years when your supply chain took twenty years to build. That wasn't an accident — it was Apple weaponizing privacy as a competitive tool while simultaneously building its own advertising business. Apple's growth playbook under Tim Cook comes down to one idea: make each existing customer worth more money every year without requiring them to buy a new phone. India and manufacturing diversification serve dual purposes: reducing China risk and opening a growth market. India's middle class is expanding, 5G infrastructure is improving, and Apple's brand aspirational value is enormous there.

A closer look at the financial trajectory of Amgen Inc. and Apple Inc. rounds out the comparison.

Amgen Inc.: Amgen reported FY2025 total revenues of $36.8 billion, up 10% year over year, and GAAP net income of $7.7 billion. Product sales grew on volume, with eighteen products reaching record annual sales and fourteen exceeding $1 billion. The Horizon acquisition continued to reshape the portfolio, while amortization, impairment charges, pricing pressure, and R&D investment kept GAAP margins below the cleaner non-GAAP picture.

Apple Inc.: Apple reported FY2025 net sales of $416.2 billion and net income of $112.0 billion. Products generated $307.0 billion of net sales, while Services reached $109.2 billion and carried a 75.4% gross margin. The financial story is no longer only iPhone unit growth: Services, custom silicon, share repurchases, installed-base retention, and ecosystem monetization have become central to Apple's profit model.